Raymond James & Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-10,616
| Closed | -$736K | – | 3575 |
|
|
2018
Q3 | $736K | Buy |
10,616
+1,015
| +11% | +$70.4K | ﹤0.01% | 2431 |
|
|
2018
Q2 | $726K | Buy |
9,601
+1,611
| +20% | +$122K | ﹤0.01% | 2416 |
|
|
2018
Q1 | $421K | Buy |
+7,990
| New | +$421K | ﹤0.01% | 2669 |
|
|
2017
Q4 | – | Sell |
-6,359
| Closed | -$379K | – | 3380 |
|
|
2017
Q3 | $379K | Buy |
6,359
+1,704
| +37% | +$102K | ﹤0.01% | 2629 |
|
|
2017
Q2 | $367K | Buy |
4,655
+766
| +20% | +$60.4K | ﹤0.01% | 2587 |
|
|
2017
Q1 | $323K | Buy |
3,889
+582
| +18% | +$48.3K | ﹤0.01% | 2650 |
|
|
2016
Q4 | $262K | Buy |
+3,307
| New | +$262K | ﹤0.01% | 2706 |
|